Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might relieve dermatitis and asthma comparably to the Regeneron Pharmaceuticals …
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
view original post